Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BI 1361849 |
Trade Name | |
Synonyms | CV9202|BI1361849 |
Drug Descriptions |
BI 1361849 (CV9202) is a cancer vaccine comprising six mRNAs for non-small cell lung cancer-associated antigens, which may result in increased immune response against tumor cells (PMID: 25288198). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C111574 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BI 1361849 | BI 1361849 | 0 | 0 |
BI 1361849 + Durvalumab + Tremelimumab | BI 1361849 Durvalumab Tremelimumab | 0 | 1 |